Page 2 - Jun Ma News Today

Vaso Corporation ("Vaso") (OTCQB:VASO) today announced that its application to trade on the OTCQX Best Market has been approved by OTC Markets Group, with the beginning of trading on OTCQX expected to be on September 26, 2023.

One of Japan’s largest investment firms with more than US$500 billion in assets under management (AUM) is spearheading an indomitable...

/PRNewswire/ -- One of Japans largest investment firms with more than US$500 billion in assets under management (AUM) is spearheading an indomitable presence...

Global investors wielding US$500 billion in capital eye new opportunities in world’s fastest growing economies at inaugural SuperBridge Summit Dubai

Global investors wielding US$500 billion in capital eye new opportunities in worlds fastest growing economies at inaugural SuperBridge Summit Dubai

Chinese President Xi Jinping on Saturday extended the countrys condolences to Moroccan King Mohammed VI over the devastating earthquake that shook the African country late on Friday night, which has caused more than 2,000 deaths as of press time.

Celebration of the man called the “Father of Army Aviation Medicine” started Monday at the Lyster Health Clinic on Fort Novosel and culminated with a birthday celebration Friday from 11

Patients with head and neck cancer and obesity saw better treatment response and survival after chemoradiation, compared with patients with the same type of cancer but a normal weight.

The addition of sintilimab to chemoradiotherapy demonstrated a significant reduction in the risk of disease recurrence or death, distant metastasis and locoregional recurrence compared with chemoradiotherapy alone as frontline therapy in patients with locally advanced nasopharyngeal carcinoma, according to findings from the phase 3 CONTINUUM trial.

Jun Ma, MD, discusses findings from the phase 3 CONTINUUM trial of sintilimab in combination with induction chemotherapy and concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma.